Siemens Healthineers AG
5-year stock timeline
Siemens Healthineers' journey from 2020 through 2026 pivots on the €16.4bn Varian acquisition—a transformational bet on oncology that reshaped the company's trajectory. The story moved through distinct phases: the deal itself and its financing, a pandemic-driven spike in rapid-test revenue that proved temporary, a grinding integration period marked by delivery friction and margin pressure, and finally a recalibration toward what management calls "New Ambition"—a more measured growth and margin recovery narrative. The share currently trades at €35.08.
Major events
2020 saw the all-cash Varian offer announced and a multi-step financing structure put in place to fund it. April 2021 closed the acquisition, consolidating oncology and therapy operations and immediately shifting revenue composition and synergy expectations. Between 2020 and 2022, COVID-19 antigen tests provided meaningful tailwind—particularly visible in FY20–21—but that support faded. The years 2022–23 brought Varian-related supply chain and delivery headwinds, procurement challenges, and margin compression that forced multiple guidance resets and sparked investor concern.
How the narrative evolved
Through 2020 and into late 2021, the market read this as transformational growth: a diagnostics-imaging-to-therapy oncology platform with near-term test revenue boosts and longer-term cross-sell potential. By 2022–23, sentiment flipped toward integration risk and margin skepticism. Varian's stumbles, cost pressures, and repeated guidance downgrades recast the stock as execution-dependent, despite the underlying strategic logic.
From 2024 onward, the framing shifted again—this time to a defensive compounder posture. Strategy 2025, or "New Ambition," positioned the company around medium-term margin and EPS targets contingent on synergy realization and cleaner execution.
What the chart shows
The March 2020 COVID crash took the share down to around €31.7, followed by a multi-month rally that peaked near €71 in December 2021. The next phase—2022 through 2023—was marked by extended correction and volatility as Varian issues and macro uncertainty produced sharp pullbacks and failed breakouts. Since 2024, trading has settled into a lower-to-mid range, roughly €30s to mid-€40s, with occasional pushes toward €50 that haven't held. The current level reflects this choppier, range-bound reality.
Key risks and downside factors
Siemens Healthineers operates across diagnostic imaging, laboratory diagnostics, and cancer care, competing directly with GE HealthCare and Philips in imaging, and Roche and Abbott in diagnostics. The competitive landscape is tilting toward integrated software and AI ecosystems, service-based contracts, and lower-cost manufacturers—a shift that's compressing both margins and the aftermarket revenue streams the company has traditionally relied on. Watch for regulatory and product-safety exposure, sensitivity to reimbursement rates and capital spending cycles, and whether management can execute on its software integration and M&A roadmap without stumbling.
- Regulatory actions and product-safety recalls could force costly remediation, constrain sales, and erode service revenue.
- Price pressure from lower-cost OEMs and third-party AI vendors poses a real threat to both market share and margins.
- Reductions in reimbursement rates, hospital capital budgets, or broader macroeconomic weakness could materially depress demand for both capital equipment and consumables.
- Integration challenges from recent acquisitions, scaling digital and software offerings, and managing the debt load could pressure both cash flow and profitability [3].
Competitive landscape
Siemens Healthineers operates in a crowded space alongside GE HealthCare, Philips, Abbott and Danaher, competing across imaging systems, clinical diagnostics and life-sciences services. The competitive landscape tilts toward companies with scale—those who can leverage hardware installed bases into service revenue—while software, AI and diagnostic consumables increasingly matter. The company has also pushed into adjacent territory: radiopharmaceuticals and oncology systems. This shapes the risk picture. Siemens Healthineers is exposed to competitor pricing and service network reach, the cyclical nature of healthcare capital spending, and the regulatory events that occasionally produce recalls or unexpected remediation costs. It's the kind of business where a product-safety action can move the needle.
| Company | Ticker |
|---|---|
| GE HealthCare Technologies, Inc. | GEHC.NASDAQ |
| Abbott Laboratories | ABT.NYSE |
| Danaher Corporation | DHR.NYSE |
Private competitors
- Carestream Health
- eviCore healthcare
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Siemens Healthineers AG
Relative Performance vs Benchmarks
| Period | Siemens Healthineers AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -0.51% | -4.77% | -5.96% |
| 3M | -16.75% | -15.79% | -26.45% |
| 6M | -16.15% | -21.21% | -26.59% |
| 1Y | -23.73% | -27.91% | -52.88% |
| 3Y | -30.69% | -87.67% | -116.36% |
| 5Y | -16.83% | -78.19% | -108.13% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 18.8 | 1.7 | 2.2 | 14.0 |
| 1Y ago | 25.7 | 2.3 | 2.9 | 17.2 |
| 3Y ago | 39.5 | 2.8 | 3.5 | 30.3 |
| 5Y ago | 31.3 | 3.3 | 3.3 | 19.4 |
Frequently Asked Questions
Where is the Siemens Healthineers AG stock traded?
What does Siemens Healthineers AG do?
What are the key metrics for SHL.XETRA?
How has Siemens Healthineers AG's stock price performed?
How is SHL.XETRA valued?
Does SHL.XETRA pay dividends?
What are the key risks when investing in SHL.XETRA?
- Regulatory actions and product-safety recalls could force costly remediation, constrain sales, and erode service revenue.
- Price pressure from lower-cost OEMs and third-party AI vendors poses a real threat to both market share and margins.
- Reductions in reimbursement rates, hospital capital budgets, or broader macroeconomic weakness could materially depress demand for both capital equipment and consumables.
- Integration challenges from recent acquisitions, scaling digital and software offerings, and managing the debt load could pressure both cash flow and profitability [web:3].
Who are the main competitors of Siemens Healthineers AG?
- GE HealthCare Technologies, Inc. (GEHC.NASDAQ)
- Abbott Laboratories (ABT.NYSE)
- Danaher Corporation (DHR.NYSE)
When does Siemens Healthineers AG report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | 2.35% | 1.85% |
| 2025 | 0.95 EUR | 1.66% | |
| 2024 | 0.95 EUR | 1.86% | |
| 2023 | 0.95 EUR | 1.85% | |
| 2022 | 0.85 EUR | 1.52% | |
| 2021 | 0.80 EUR | 1.64% | |
| 2020 | 0.80 EUR | 1.94% | |
| 2019 | 0.70 EUR | 1.98% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 23.38B | 22.36B | 21.68B | 21.71B | 18.00B |
| Operating income (EBIT) | 3.44B | 3.30B | 2.44B | 3.06B | 2.78B |
| Net income | 2.14B | 1.94B | 1.51B | 2.04B | 1.73B |
| Free cash flow | 2.27B | 1.77B | 1.28B | 1.65B | 2.26B |
| Total assets | 44.37B | 46.05B | 46.68B | 49.06B | 41.93B |
| Equity | 18.04B | 18.20B | 18.08B | 19.84B | 16.04B |
| Net debt | 12.89B | 13.53B | -1.01B | -704.00M | 12.99B |
PWP Leeway UG (haftungsbeschränkt)
